161 related articles for article (PubMed ID: 30209066)
1. The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia.
Calore F; Londhe P; Fadda P; Nigita G; Casadei L; Marceca GP; Fassan M; Lovat F; Gasparini P; Rizzotto L; Zanesi N; Jackson D; Mehta S; Nana-Sinkam P; Sampath D; Pollock RE; Guttridge DC; Croce CM
Cancer Res; 2018 Dec; 78(23):6680-6690. PubMed ID: 30209066
[TBL] [Abstract][Full Text] [Related]
2. Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90.
Zhang G; Liu Z; Ding H; Zhou Y; Doan HA; Sin KWT; Zhu ZJ; Flores R; Wen Y; Gong X; Liu Q; Li YP
Nat Commun; 2017 Sep; 8(1):589. PubMed ID: 28928431
[TBL] [Abstract][Full Text] [Related]
3. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7.
He WA; Calore F; Londhe P; Canella A; Guttridge DC; Croce CM
Proc Natl Acad Sci U S A; 2014 Mar; 111(12):4525-9. PubMed ID: 24616506
[TBL] [Abstract][Full Text] [Related]
4. IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.
Balak DM; van Doorn MB; Arbeit RD; Rijneveld R; Klaassen E; Sullivan T; Brevard J; Thio HB; Prens EP; Burggraaf J; Rissmann R
Clin Immunol; 2017 Jan; 174():63-72. PubMed ID: 27876460
[TBL] [Abstract][Full Text] [Related]
5. A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis.
Jiang W; Zhu FG; Bhagat L; Yu D; Tang JX; Kandimalla ER; La Monica N; Agrawal S
J Invest Dermatol; 2013 Jul; 133(7):1777-84. PubMed ID: 23370539
[TBL] [Abstract][Full Text] [Related]
6. The Toll-Like Receptor/MyD88/XBP1 Signaling Axis Mediates Skeletal Muscle Wasting during Cancer Cachexia.
Bohnert KR; Goli P; Roy A; Sharma AK; Xiong G; Gallot YS; Kumar A
Mol Cell Biol; 2019 Aug; 39(15):. PubMed ID: 31138662
[TBL] [Abstract][Full Text] [Related]
7. A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis.
Kim YJ; Schiopu E; Dankó K; Mozaffar T; Chunduru S; Lees K; Goyal NA; Sarazin J; Fiorentino DF; Sarin KY
J Am Acad Dermatol; 2021 Apr; 84(4):1160-1162. PubMed ID: 32781178
[No Abstract] [Full Text] [Related]
8. Circulating Plasma Extracellular Vesicles from Septic Mice Induce Inflammation via MicroRNA- and TLR7-Dependent Mechanisms.
Xu J; Feng Y; Jeyaram A; Jay SM; Zou L; Chao W
J Immunol; 2018 Dec; 201(11):3392-3400. PubMed ID: 30355788
[TBL] [Abstract][Full Text] [Related]
9. Ameliorating cancer cachexia by inhibiting cancer cell release of Hsp70 and Hsp90 with omeprazole.
Liu Z; Xiong J; Gao S; Zhu MX; Sun K; Li M; Zhang G; Li YP
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):636-647. PubMed ID: 34729960
[TBL] [Abstract][Full Text] [Related]
10. Lung cancer-derived extracellular vesicles induced myotube atrophy and adipocyte lipolysis via the extracellular IL-6-mediated STAT3 pathway.
Hu W; Ru Z; Zhou Y; Xiao W; Sun R; Zhang S; Gao Y; Li X; Zhang X; Yang H
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Aug; 1864(8):1091-1102. PubMed ID: 31002945
[TBL] [Abstract][Full Text] [Related]
11. ZIP4 Promotes Muscle Wasting and Cachexia in Mice With Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles From Cancer Cells.
Yang J; Zhang Z; Zhang Y; Ni X; Zhang G; Cui X; Liu M; Xu C; Zhang Q; Zhu H; Yan J; Zhu VF; Luo Y; Hagan JP; Li Z; Fang J; Jatoi A; Fernandez-Zapico ME; Zheng L; Edil BH; Bronze MS; Houchen CW; Li YP; Li M
Gastroenterology; 2019 Feb; 156(3):722-734.e6. PubMed ID: 30342032
[TBL] [Abstract][Full Text] [Related]
12. Expression of CCAAT/Enhancer Binding Protein Beta in Muscle Satellite Cells Inhibits Myogenesis in Cancer Cachexia.
Marchildon F; Lamarche É; Lala-Tabbert N; St-Louis C; Wiper-Bergeron N
PLoS One; 2015; 10(12):e0145583. PubMed ID: 26709824
[TBL] [Abstract][Full Text] [Related]
13. Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling.
Pettersen K; Andersen S; Degen S; Tadini V; Grosjean J; Hatakeyama S; Tesfahun AN; Moestue S; Kim J; Nonstad U; Romundstad PR; Skorpen F; Sørhaug S; Amundsen T; Grønberg BH; Strasser F; Stephens N; Hoem D; Molven A; Kaasa S; Fearon K; Jacobi C; Bjørkøy G
Sci Rep; 2017 May; 7(1):2046. PubMed ID: 28515477
[TBL] [Abstract][Full Text] [Related]
14. The Pathway to Cancer Cachexia: MicroRNA-Regulated Networks in Muscle Wasting Based on Integrative Meta-Analysis.
Freire PP; Fernandez GJ; Cury SS; de Moraes D; Oliveira JS; de Oliveira G; Dal-Pai-Silva M; Dos Reis PP; Carvalho RF
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013615
[TBL] [Abstract][Full Text] [Related]
15. A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice.
Zhu FG; Jiang W; Bhagat L; Wang D; Yu D; Tang JX; Kandimalla ER; La Monica N; Agrawal S
Autoimmunity; 2013 Nov; 46(7):419-28. PubMed ID: 24083389
[TBL] [Abstract][Full Text] [Related]
16. Toll-Like Receptor-4 Disruption Suppresses Adipose Tissue Remodeling and Increases Survival in Cancer Cachexia Syndrome.
Henriques F; Lopes MA; Franco FO; Knobl P; Santos KB; Bueno LL; Correa VA; Bedard AH; Guilherme A; Birbrair A; Peres SB; Farmer SR; Batista ML
Sci Rep; 2018 Dec; 8(1):18024. PubMed ID: 30575787
[TBL] [Abstract][Full Text] [Related]
17. Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.
Lai CY; Su YW; Lin KI; Hsu LC; Chuang TH
J Immunol Res; 2017; 2017():7807313. PubMed ID: 28894754
[TBL] [Abstract][Full Text] [Related]
18. Morin suppresses cachexia-induced muscle wasting by binding to ribosomal protein S10 in carcinoma cells.
Yoshimura T; Saitoh K; Sun L; Wang Y; Taniyama S; Yamaguchi K; Uchida T; Ohkubo T; Higashitani A; Nikawa T; Tachibana K; Hirasaka K
Biochem Biophys Res Commun; 2018 Dec; 506(4):773-779. PubMed ID: 30389140
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.
Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ
Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276
[TBL] [Abstract][Full Text] [Related]
20. Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation.
Suárez-Fariñas M; Arbeit R; Jiang W; Ortenzio FS; Sullivan T; Krueger JG
PLoS One; 2013; 8(12):e84634. PubMed ID: 24386404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
